Biphasic lipid-vesicle compositions
AssigneeHelix BioPharma Corporation
InventorsMarianna Foldvari, Praveen Kumar, John M. Docherty
Life of this patent
Estimating the term…
Abstract
A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.
Claims9
A biphasic vesicle composition comprising:
- (a) a first phase comprising an oil-in-water emulsion which itself comprises oil, water, interferon alpha-2b and methionine;
- and
- (b) a second phase comprising multilamellar lipid vesicles suspended in said first phase wherein said vesicles contain entrapped therein a composition comprising an oil-in-water emulsion which itself comprises oil, water, interferon alpha-2b and methionine,
- wherein each phase comprises an amount sufficient of methionine to stabilize said interferon alpha-2b against oxidation,
- wherein said methionine is the amino acid methionine of the chemical structure:
- further wherein said composition comprises a therapeutically effective aggregate amount of said interferon alpha-2b.
Dependencies are inferred from the claim text.